Mechanism-Driven Therapy
for Chronic Wound Healing
Mechanism Validated in Phase II Clinical Studies
CLINICALLY VALIDATED
Second Phase II
completed in venous leg ulcer patients, demonstrating effective debridement and accelerated healing
DUAL-ACTION MECHANISM
Heals + Debrides
continuous enzymatic debridement and activation of endogenous repair signalling
DESIGNED FOR CLINICAL USE
Practical
easy application, strong safety profile, and compatibility with standard care workflows
Aurase Wound Gel
Our Solution
AURASE WOUND GEL
Aurase Wound Gel contains tarumase, a highly specific fibrinolytic enzyme cloned from maggot saliva
It is optimised for selective removal of devitalised tissue and formulated within a hydrogel for practical clinical use
Aurase Wound Gel is easy to apply and designed to integrate into standard wound care workflows without additional procedural burden or patient discomfort
It can be used at all stages of the wound healing journey, from early stage to wound closure, in all settings
Key Characteristics of Aurase Wound Gel
100% Standard of care fit
Simple application during standard dressing changes
Temperature stable: Ideal for community use
Safe: No risk if left on wound; specificity & pH-dependent action spares healthy tissue
Equally well suited to clinic & hospital environments
High compatibility with established wound care products
Aurase Wound Gel is positioned to become the “go-to” first line healing & debridement therapy for all chronic wounds
MECHANISM OF ACTION
Actively heals: Activation of endogenous repair pathways (PAR2 receptors) involved in cell migration, proliferation, and tissue regeneration
Continuously debrides: Degrades fibrin anchors & co-opted fibrin for elastin & collagen
Optimises wound bed for healing: Hydrogel provides moist environment and supports cell migration
Aurase Wound Gel has completed its second Phase II clinical evaluation, validating its dual-action mechanism and demonstrating a substantial acceleration of healing compared with standard care
Full results will be reported in the forthcoming clinical study report
Proof-of-Concept
-
Tarumase successfully debrides wounds faster
-
More complete debridement & improved healing at increased enzyme concentrations
Strong Safety Profile
-
No indications of systemic absorption
-
No antibody generation
-
No systemic effects on coagulation
Pain-free
-
Does not add to patients’ already existing pain burden
-
No evidence of local tolerability issues
Development pipeline
Our Phase II trials explore debridement and healing in venous leg ulcers
